E6742, a selective dual antagonist for TLR7/8, has been investigated in a double-blind phase 1/2 study in SLE, and 57.1% of patients achieved a positive response on the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA), compared with 33.3% in the placebo group (87). The gene discussed is TLR7; the disease is systemic lupus erythematosus.